A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Na ïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

ConclusionsSafety data for afatinib when used in a “near real-world” setting in patients withEGFRm+ NSCLC was consistent with the known safety profile of afatinib. Supporting efficacy data of afatinib were provided in all patients, and in those enrolled in China. Tolerability-guided afatinib dose reduction allowed patients to remain on treatment and continue to experience clinical benefit.Trial Registration Number and Date of RegistrationNCT01953913 (1 October 2013).
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research